Encompass Health Corporation $EHC Stake Boosted by Inspire Investing LLC

Inspire Investing LLC boosted its holdings in Encompass Health Corporation (NYSE:EHC) by 22.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 49,812 shares of the company’s stock after purchasing an additional 9,165 shares during the quarter. Inspire Investing LLC owned approximately 0.05% of Encompass Health worth $4,818,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of EHC. Northwestern Mutual Wealth Management Co. boosted its position in Encompass Health by 3,059,159.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after purchasing an additional 3,793,358 shares during the period. AlphaCore Capital LLC acquired a new stake in Encompass Health in the fourth quarter worth $4,881,000. Tudor Investment Corp ET AL increased its position in Encompass Health by 155.3% in the third quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock worth $26,765,000 after buying an additional 128,191 shares during the period. SG Americas Securities LLC lifted its stake in Encompass Health by 1,070.9% in the fourth quarter. SG Americas Securities LLC now owns 88,054 shares of the company’s stock valued at $9,346,000 after buying an additional 80,534 shares during the last quarter. Finally, Cinctive Capital Management LP boosted its holdings in shares of Encompass Health by 48.6% during the third quarter. Cinctive Capital Management LP now owns 66,898 shares of the company’s stock valued at $8,497,000 after acquiring an additional 21,887 shares during the period. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Trading Down 0.7%

NYSE:EHC opened at $100.60 on Tuesday. The stock has a market cap of $9.98 billion, a price-to-earnings ratio of 16.79, a PEG ratio of 2.21 and a beta of 0.72. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. Encompass Health Corporation has a 1 year low of $92.77 and a 1 year high of $127.99. The business has a fifty day moving average of $103.15 and a 200-day moving average of $103.49.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The company’s revenue was up 9.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities analysts predict that Encompass Health Corporation will post 5.97 earnings per share for the current year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be paid a $0.19 dividend. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio is currently 12.69%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Barclays lowered their price target on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research report on Tuesday, May 5th. TD Cowen assumed coverage on shares of Encompass Health in a research note on Thursday, May 28th. They set a “buy” rating and a $125.00 target price for the company. Weiss Ratings cut shares of Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, Leerink Partners set a $152.00 price target on Encompass Health in a report on Friday, May 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $143.86.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the transaction, the executive vice president directly owned 24,755 shares in the company, valued at $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.80% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.